EA
TRIB

Emerald Acquisition’s Trinity Biotech TRIB Stock Holding History

Emerald Acquisition’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$5.14M Sell
77,709
-12,398
-14% -$772K 0.01% 1200
2016
Q2 		$5.11M Buy
+90,107
New +$5.08M 0.01% 1302

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Emerald Acquisition's TRIB Position: Q3 2016 in Review

Emerald Acquisition reduced its Trinity Biotech (TRIB) stake by 14% in Q3 2016, selling an estimated $772K and leaving 77,709 shares worth $5.14M. The position accounts for 0.01% of the portfolio, ranked #1200.

Emerald Acquisition first reported a position in TRIB in Q2 2016 and has held it in 2 quarters since. 79 funds tracked by Wall St. Rank hold TRIB as of Q3 2016.

  • Emerald Acquisition held 77,709 shares of Trinity Biotech worth $5.14M as of Q3 2016.
  • Emerald Acquisition sold 12,398 Trinity Biotech shares in Q3 2016, an estimated $772K.
  • Trinity Biotech made up 0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1200 holding.
  • Emerald Acquisition first reported a position in Trinity Biotech in Q2 2016 and has held it in 2 quarters since.
  • 79 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.